LLY

Biopharma pricing power will be the key swing factor for Q2 earnings as companies with cleaner growt

Eli Lilly (LLY) could deliver a "beat-and-raise" second quarter, driven by US prescription growth fo

AbbVie ABBV remains a dominant force in the immunology segment, from where it generates nearly half of its top line. This growth is mainly driven by the continued uptake of its two blockbuster medications, Skyrizi and Rinvoq, which have helped the company return to top-line growth despite the U.S. loss of exclusivity for its legacy drug, Humira, in 2023. Investors’ focus will primarily be on the sales performance of these two drugs when AbbVie reports its second-quarter 2026 results on July 31. The Zacks Consensus Estimate for Skyrizi sales is pegged at $5.49 billion, while the same for Rinvoq stands at $2.47 billion. Continued momentum from these therapies, supported by market share gains, is expected to drive immunology sales in the quarter. Meanwhile, Humira sales are expected to continue their downward trajectory, with the Zacks Consensus Estimate pegged at $744 million for the quarter. AbbVie successfully launched Skyrizi and Rinvoq across Humira's major indications, as well as a distinct new indication, atopic dermatitis. Both drugs have delivered strong performance across approved indications, especially in the popular inflammatory bowel disease (IBD) space, which includes ulcerative colitis (UC) and Crohn’s disease (CD). The company has also been expanding its presence beyond immunology into oncology and neuroscience. In recent years, ABBV has added Elahere, Emrelis and, most recently, Decnupaz, bringing its total number of oncology therapies to six. Growth in its neuroscience segment has also been supported by the increasing uptake of its migraine drugs, Ubrelvy and Qulipta, as well as the Parkinson’s disease drug Vyalev. The immunology market is highly competitive. A key player in this area is Johnson & Johnson JNJ, which already markets two blockbuster drugs — Stelara and Tremfya. These medications are approved across multiple immunology indications, including UC and CD. Since Stelara lost U.S. patent exclusivity last year, J&J has shifted its focus to Tremfya. It recently secured approval for a new immunology drug, Icotyde, to treat moderate-to-severe plaque psoriasis. While still in the early stages of launch, the drug could pose a competitive threat to Skyrizi. Another pharma giant expanding its presence in immunology is Eli Lilly LLY, following the FDA approval of Omvoh for the UC indication in late 2023. Omvoh marked LLY’s first immunology dr...

Johnson & Johnson stock is Monday's IBD Stock Of The Day. The medical bellwether will report its June-quarter earnings next week.

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Eli Lilly stock has surged over the past five years, and at around US$1,213 a share, investors are weighing a sharp share price gain against signals that the stock screens as expensive on several checks even as a Discounted Cash Flow (DCF) estimate points to upside. A roughly 441.5% return over five years puts Eli Lilly among the stronger long term performers, which raises the bar for what counts as an attractive entry point. Expectations around the GLP-1 obesity and diabetes franchise can support a higher intrinsic value, while regulatory and pricing scrutiny, including recent attention on China trials and reimbursement, may limit how much investors are willing to pay for that growth. With Eli Lilly only passing 2 of 6 valuation checks, the broader picture leans more toward an expensive stock than a clear bargain, even with a DCF suggesting it trades about 23.7% below an intrinsic value estimate based on projected cash flows (2/6 valuation score). The issue now is whether Eli Lilly's current price already reflects enough of that GLP-1 and pipeline optimism, or if the DCF style intrinsic value estimate still leaves a reasonable margin between market price and fundamentals. Eli Lilly delivered 56.6% returns over the last year. See how this stacks up to the rest of the Pharmaceuticals industry. The Discounted Cash Flow (DCF) model here takes Eli Lilly's projected cash flows and discounts them back to today using a 2 stage Free Cash Flow to Equity approach. Over the latest twelve months, Eli Lilly generated about $8.6b in free cash flow, and the model assumes those cash flows keep growing from this base rather than shrinking, which results in a higher intrinsic value than many mature pharmaceutical companies. On these assumptions, the DCF estimates an intrinsic value of about $1,591 per share, compared with a current share price around $1,213, implying the stock screens roughly 23.7% undervalued. The Medicare GLP-1 Bridge program, which broadens access to Eli Lilly's obesity drugs on a capped copay, helps explain why cash flow expectations embedded in the model remain strong even though headline valuation multiples appear elevated. Overall, this DCF view suggests that Eli Lilly stock may be trading below the model's estim...

LLY is one of the world’s most valuable healthcare companies, creating medicines for diabetes, oncology, immunology, neuroscience, and obesity, along with using advanced technologies and AI to make more treatments. The company’s first-quarter fiscal 2026 earnings report, LLY showed $19.8 billion in quarterly revenue (a 56% year-over-year gain) led by its Zepbound and Mounjaro products ($12.8 billion together) that will soon be covered by Medicare, non-GAAP per-share earnings of $8.55 (a 156% annual jump), and offered annual guidance of up to $85 billion and $37 for revenue and EPS, respectively. It’s no wonder LLY shares are up 12% this year, and they could rise more. MoneyFlows data shows how Big Money investors are again betting heavily on the stock. Institutional volumes reveal plenty. In the last year, LLY has endured some choppiness. But it’s once again enjoying strong investor demand, which we believe to be institutional support. Each green bar signals unusually large volumes in LLY shares. They reflect our proprietary inflow signal, pushing the stock higher: Plenty of health care names are under accumulation right now. But there’s a powerful fundamental story happening with Eli Lilly. Institutional support and a healthy fundamental backdrop make this company worth investigating. As you can see, LLY has had strong sales and earnings growth: 3-year sales growth rate (+32.1%) 3-year EPS growth rate (+60.6%) Source: FactSet Also, EPS is estimated to ramp higher this year by +21.7%. Now it makes sense why the stock has been generating Big Money interest. LLY has a track record of strong financial performance. Marrying great fundamentals with MoneyFlows software has found some big winning stocks over the long term. Eli Lilly has been a top-rated stock at MoneyFlows for years. That means the stock has unusual buy pressure and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis. In the last year, LLY has drawn five outlier inflow signals and is up 53.9%. The blue bars below show when LLY was a top pick on the Outlier 20 report…institutions remain buyers: Tracking unusual volumes reveals the power of money flows. This is a trait that most outlier stocks exhibit…the best of the best. Big Money demand drives stocks upward. The LLY action isn’t new at all. Big Money buying in the shares is signaling to take notice. Gi...

Eli Lilly and Company (NYSE:LLY) is one of the high growth stocks to buy right now. On June 14, Eli Lilly announced positive results from the Phase 3 BRUIN CLL-322 clinical trial, which evaluated the addition of Jaypirca (pirtobrutinib) to a time-limited venetoclax and rituximab regimen for patients with relapsed or refractory chronic lymphocytic leukemia/CLL or small lymphocytic lymphoma/SLL. The study met its primary endpoint, showing that the pirtobrutinib combination reduced the risk of disease progression or death by 45% compared to the control arm of venetoclax and rituximab alone. The trial enrolled 639 patients, nearly 80% of whom had been previously treated with a covalent BTK inhibitor, making the findings highly relevant to current clinical practices. At a median follow-up of 27.3 months, the median progression-free survival/PFS in the pirtobrutinib arm had not been reached, compared to 39.7 months in the control arm. These benefits were consistent across various high-risk patient subgroups, and the pirtobrutinib combination also showed a significant advantage in the time to next treatment. The safety profile of the regimen was consistent with the known profiles of the individual medicines, with minimal additive toxicity observed when adding pirtobrutinib. Discontinuation rates due to treatment-related adverse events were similar between the two study arms. Based on these findings, Eli Lilly and Company (NYSE:LLY) plans to submit the data to global regulatory authorities with the goal of expanding the use of Jaypirca as a potential new standard of care in previously treated CLL/SLL populations. Eli Lilly and Company (NYSE:LLY) is a healthcare company that develops human pharmaceutical products, including cardiometabolic health, oncology, and immunology products. While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. Disclosure: None. Follow Insider Monkey on Google News.

Earnings are coming up for Nike as the company tries to engineer a turnaround, but Nike stock continues to plumb 52-week lows.

INDIANAPOLIS, June 22, 2026 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2026 of $1.73 per share on outstanding common stock. The dividend is payable on September 10, 2026, to shareholders of record at the close of business on August 14, 2026. About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. F-LLY Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about expected dividend payments and reflects Lilly's current beliefs and expectations. However, there are significant risks and uncertainties in pharmaceutical research and development, as well as in business development activities and capital allocation strategies related to the company's business and actual results may differ materially due to various factors. For further discussion of risks and uncertainties relevant to Lilly's business that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this rele...

With the massive SpaceX debut hogging the headlines, some retail investors may have allowed more prosaic names to slip from their minds. Pharma stock Eli Lilly is trading in a buy zone as institutional investors load up. Eli Lilly is committed to innovation and reinvests 20%-25% of its sales back into developing new treatments.

On this episode of Stock Movers with Alexis Christoforous: - Shares of The Campbell's Company (CPB) edged higher ahead of the US market open after the canned soup maker reported adjusted earnings per share for the third quarter that beat the average analyst estimate. - Eli Lilly (LLY) shares gained in the early session following obesity drug presentations at the American Diabetes Association conference. Citi analysts say their conviction on Lilly is firmly intact, given the company's incretin portfolio is "not built around singular blockbusters." - Shares of Marvell Technology (MRVL) and Flex (FLEX) are rising in premarket trading as the companies are set to replace Pool Corp. and Campbell's in S&P 500 before the market open on June 22, S&P Dow Jones Indices says in emailed statement.

As of 1 p.m. ET, the S&P 500 (SNPINDEX:^GSPC) rose 0.49% to 7,557.17, the Nasdaq Composite (NASDAQINDEX:^IXIC) gained 0.65% to 26,847.19 on tech strength, while the Dow Jones Industrial Average (DJINDICES:^DJI) slipped 0.01% to 50,641.15, lagging growth benchmarks but holding near record territory. Snowflake surged after blowout Q1 earnings and a $6 billion deal with Amazon, while Microsoft advanced on plans to deploy in-house coding AI models. In healthcare, Eli Lilly gained as CVS restored coverage for the obesity drug Zepbound, and France became the first EU country to cover weight loss drugs in certain cases. Snowflake is today’s headlining stock, rising 38% after reporting Q1 earnings after earnings yesterday. The cloud-based data platform provider grew sales by 33%, agreed to a $6 billion deal with Amazon, and now counts 813 of the Forbes Global 2000 as customers. The AI boom remains a major tailwind for the company. Elsewhere, it was a good day for many consumer-facing stocks. Dollar Tree, Best Buy, and Hormel are up 19%, 18%, and 13%, respectively, today after each stock reported earnings. I’d argue that these results are promising for the broader economy, especially after Walmart and Target's earnings last week showed that the U.S. consumer remains surprisingly resilient. The S&P 500’s biggest loser so far today is Synopsys, despite the semiconductor design company’s earnings beat and raised guidance. Investors shouldn’t panic over the company’s 9% decline today, especially considering the company has been a 9-bagger over the last decade. Before you buy stock in S&P 500 Index, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and S&P 500 Index wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $471,072!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,303,352!* Now, it’s worth noting Stock Advisor’s total average return is 983% — a market-crushing outperformance compared to 210% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individu...